Tue, November 21, 2017
Mon, November 20, 2017
Fri, November 17, 2017
Thu, November 16, 2017
Wed, November 15, 2017
Tue, November 14, 2017
Mon, November 13, 2017
Fri, November 10, 2017
Thu, November 9, 2017
Wed, November 8, 2017
Tue, November 7, 2017

Liav Abraham Maintained (TEVA) at Hold with Decreased Target to $13 on, Nov 13th, 2017


//stocks-investing.news-articles.net/content/201 .. ith-decreased-target-to-13-on-nov-13th-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Liav Abraham of Citigroup, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Hold with Decreased Target from $19 to $13 on, Nov 13th, 2017.

Liav has made no other calls on TEVA in the last 4 months.



There are 9 other peers that have a rating on TEVA. Out of the 9 peers that are also analyzing TEVA, 5 agree with Liav's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gregg Gilbert of "Deutsche Bank" Downgraded from Strong Buy to Hold on, Friday, November 3rd, 2017
  • Douglas Tsao of "Barclays" Maintained at Hold with Decreased Target to $19 on, Friday, October 20th, 2017
  • Tyler Van Buren of "Cowen & Co." Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Aaron Gal of "Bernstein" Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Derek Archila of "Oppenheimer" Downgraded from Buy to Hold on, Thursday, August 3rd, 2017


These are the ratings of the 4 analyists that currently disagree with Liav


  • Vamil Divan of "Credit Suisse" Maintained at Sell with Decreased Target to $8 on, Monday, November 6th, 2017
  • David Risinger of "Morgan Stanley" Maintained at Sell with Decreased Target to $7 on, Friday, November 3rd, 2017
  • Tim Chiang of "BTIG" Upgraded from Hold to Strong Buy and Held Target at $24 on, Monday, September 11th, 2017
  • Randall Stanicky of "RBC Capital" Downgraded from Buy to Sell on, Friday, August 4th, 2017

Publication Contributing Sources